Travere Therapeutics Named Finalist for the 2022 PM360 Magazine Trailblazer Specialty Pharma/Biotech Company of the Year Award

2022 PM 360 Trailblazer Specialty Pharma/Biotech Company of the Year Finalist

Wednesday, August 17, 2022 — We are thrilled to have been named as a finalist for the 2022 PM30 Magazine Trailblazer Specialty Pharma/Biotech Company of the Year award. Trailblazer finalists are selected by a cross-section of experts from across the industry evaluating companies for innovation, talent development, and social responsibility. Read the full list of finalists.

Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy